Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Not all patients with a diagnosis of a radial scar require excision.

Eghtedari M, Le-Petross H, Babiera GV, Albarracin CT, Hess KR, Woodtichartpreecha P, Whitman GJ.

Breast J. 2019 Jul;25(4):792-794. doi: 10.1111/tbj.13329. Epub 2019 May 13. No abstract available.

PMID:
31087426
2.

The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.

Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I.

Breast Cancer Res. 2018 Dec 11;20(1):150. doi: 10.1186/s13058-018-1074-z.

3.

Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation.

Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM.

Ann Surg. 2019 Jan;269(1):150-157. doi: 10.1097/SLA.0000000000002439.

PMID:
28742682
4.

Pseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review With Pathologic Correlation.

Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, Posleman Monetto FE, Whitman GJ.

Curr Probl Diagn Radiol. 2017 Mar - Apr;46(2):130-135. doi: 10.1067/j.cpradiol.2016.01.005. Epub 2016 Feb 2. Review.

PMID:
26949063
5.

High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.

Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B.

Cancer. 2015 Oct 1;121(19):3422-7. doi: 10.1002/cncr.29572. Epub 2015 Aug 17.

6.

Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.

Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian I.

PLoS One. 2015 May 22;10(5):e0127678. doi: 10.1371/journal.pone.0127678. eCollection 2015.

7.

The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.

Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA.

Clin Cancer Res. 2015 Jun 1;21(11):2580-90. doi: 10.1158/1078-0432.CCR-14-2191. Epub 2015 Mar 4.

8.

Molecular cytogenetic characterization of mammary neuroendocrine carcinoma.

Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y.

Hum Pathol. 2014 Sep;45(9):1951-6. doi: 10.1016/j.humpath.2014.06.002. Epub 2014 Jun 18.

PMID:
25074542
9.

Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis.

Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I.

PLoS One. 2014 May 8;9(5):e97076. doi: 10.1371/journal.pone.0097076. eCollection 2014.

10.

Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database.

Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y.

BMC Cancer. 2014 Mar 4;14:147. doi: 10.1186/1471-2407-14-147.

11.

The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer.

Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo L.

Mod Pathol. 2013 Jan;26(1):71-8. doi: 10.1038/modpathol.2012.135. Epub 2012 Aug 17.

12.

Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast.

Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT.

Am J Surg Pathol. 2012 Sep;36(9):1353-8. doi: 10.1097/PAS.0b013e318259ef7f.

PMID:
22895267
13.

Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.

Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP 3rd, Powell SZ, Fuller GN.

Ann Diagn Pathol. 2012 Aug;16(4):255-9. doi: 10.1016/j.anndiagpath.2011.11.003. Epub 2012 Mar 23.

PMID:
22445362
14.

Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.

Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK.

Breast Cancer Res Treat. 2012 Jun;133(3):1131-41. doi: 10.1007/s10549-012-1999-3. Epub 2012 Mar 4.

15.

Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.

Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP 3rd, Powell SZ, Goodman JC, Fuller GN.

Ann Diagn Pathol. 2012 Jun;16(3):161-70. doi: 10.1016/j.anndiagpath.2011.08.010. Epub 2011 Dec 24.

PMID:
22197544
16.

Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.

Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.

Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25. Erratum in: Cancer. 2014 Mar 15;120(6):927.

17.

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.

Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK.

Breast Cancer Res Treat. 2011 Nov;130(1):145-53. doi: 10.1007/s10549-011-1711-z. Epub 2011 Aug 10.

18.

Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges.

Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y.

Histopathology. 2011 Jul;59(1):106-15. doi: 10.1111/j.1365-2559.2011.03880.x. Epub 2011 Jun 13.

PMID:
21668471
19.

Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation.

Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y.

Hum Pathol. 2011 Aug;42(8):1169-77. doi: 10.1016/j.humpath.2010.11.014. Epub 2011 Feb 21.

PMID:
21334720
20.

Triple-negative breast cancer: what the radiologist needs to know.

Whitman GJ, Albarracin CT, Gonzalez-Angulo AM.

Semin Roentgenol. 2011 Jan;46(1):26-39. doi: 10.1053/j.ro.2010.09.004. Review. No abstract available.

PMID:
21134526
21.

Identifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy.

Albarracin CT, Nguyen CV, Whitman GJ, Yang W, Sneige N.

Radiology. 2010 Dec;257(3):893-4; author reply 984. doi: 10.1148/radiol.101253. No abstract available. Erratum in: Radiology. 2011 Mar;258(3):962. Weiang, Wei [corrected to Yang, Wei].

PMID:
21084420
22.

Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast.

Resetkova E, Khazai L, Albarracin CT, Arribas E.

Breast J. 2010 Nov-Dec;16(6):573-80. doi: 10.1111/j.1524-4741.2010.01013.x.

PMID:
21070433
23.

Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision.

Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N.

Ann Surg Oncol. 2011 Mar;18(3):752-61. doi: 10.1245/s10434-010-1127-8. Epub 2010 Oct 23.

PMID:
20972636
24.

MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.

Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra R.

Am J Pathol. 2009 May;174(5):1940-8. doi: 10.2353/ajpath.2009.080718. Epub 2009 Mar 26.

25.

High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT.

Cancer Prev Res (Phila). 2009 Feb;2(2):122-7. doi: 10.1158/1940-6207.CAPR-08-0050. Epub 2009 Jan 27.

26.

Ductal carcinoma in situ: state of the science and roadmap to advance the field.

Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN.

J Clin Oncol. 2009 Jan 10;27(2):279-88. doi: 10.1200/JCO.2008.18.3103. Epub 2008 Dec 8. Review.

PMID:
19064970
27.

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK.

J Clin Oncol. 2008 Sep 10;26(26):4282-8. doi: 10.1200/JCO.2008.16.6231.

28.

Loss of annexin A1 expression in breast cancer progression.

Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT.

Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):530-4. doi: 10.1097/PAI.0b013e31817432c3.

PMID:
18776816
29.

MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers.

Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CT.

Oncogene. 2008 Nov 6;27(52):6667-78. doi: 10.1038/onc.2008.256. Epub 2008 Jul 28.

PMID:
18663355
30.

Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution.

Resetkova E, Edelweiss M, Albarracin CT, Yang WT.

Breast Cancer Res Treat. 2011 Jun;127(2):335-43. doi: 10.1007/s10549-008-0119-x. Epub 2008 Jul 15.

PMID:
18626769
31.

Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma.

Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CT.

Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):451-5.

PMID:
18091390
32.

Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases.

Ferreira M, Albarracin CT, Resetkova E.

Mod Pathol. 2008 Feb;21(2):201-7. Epub 2007 Dec 14.

33.

Giant cell tumor of soft tissue arising in breast.

May SA, Deavers MT, Resetkova E, Johnson D, Albarracin CT.

Ann Diagn Pathol. 2007 Oct;11(5):345-9. Epub 2007 Jul 24.

PMID:
17870021
34.

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.

Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT.

Cancer. 2007 Feb 15;109(4):658-67. Erratum in: Cancer. 2009 May 1;115(9):2024. Reseetkova, Erika [corrected to Resetkova, Erika].

36.

Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.

Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT.

Clin Cancer Res. 2006 Aug 1;12(15):4598-604.

37.

A large, fungating breast mass. Secretory carcinoma with apocrine differentiation.

Anderson P, Albarracin CT, Resetkova E.

Arch Pathol Lab Med. 2006 Apr;130(4):e50-2. No abstract available.

PMID:
16594759
38.

The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype.

Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J.

Oncol Rep. 2004 Dec;12(6):1217-9.

PMID:
15547740
39.

Expression of sigma 1 receptor in human breast cancer.

Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Hortobagyi GN, Pusztai L.

Breast Cancer Res Treat. 2004 Oct;87(3):205-14. Erratum in: Breast Cancer Res Treat. 2005 Jan;89(1):95. Marcelo, AC [corrected to Marcelo Aldaz, C].

PMID:
15528963
40.

Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer.

Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra R.

Mod Pathol. 2004 Jan;17(1):75-80.

41.

Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma.

Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF.

Hum Pathol. 2000 Jun;31(6):672-7.

PMID:
10872659
42.
43.

The different forms of the prolactin receptor in the rat corpus luteum: developmental expression and hormonal regulation in pregnancy.

Telleria CM, Parmer TG, Zhong L, Clarke DL, Albarracin CT, Duan WR, Linzer DI, Gibori G.

Endocrinology. 1997 Nov;138(11):4812-20.

PMID:
9348210
44.

PRAP, a prolactin receptor associated protein: its gene expression and regulation in the corpus luteum.

Duan WR, Parmer TG, Albarracin CT, Zhong L, Gibori G.

Endocrinology. 1997 Aug;138(8):3216-21.

PMID:
9231770
45.

Transcriptional activation of the gonadotropin-releasing hormone receptor gene by activin A.

Fernández-Vázquez G, Kaiser UB, Albarracin CT, Chin WW.

Mol Endocrinol. 1996 Apr;10(4):356-66.

PMID:
8721981
46.
47.

Isolation and characterization of a rat luteal cDNA encoding 20 alpha-hydroxysteroid dehydrogenase.

Mao J, Duan WR, Albarracin CT, Parmer TG, Gibori G.

Biochem Biophys Res Commun. 1994 Jun 30;201(3):1289-95.

PMID:
8024573
49.

Prolactin regulation of the calmodulin-dependent protein kinase III elongation factor-2 system in the rat corpus luteum.

Albarracin CT, Palfrey HC, Duan WR, Rao MC, Gibori G.

J Biol Chem. 1994 Mar 11;269(10):7772-6.

50.

Hormonal and immunological characterization of the 32 kilodalton ovarian-specific protein.

Parmer TG, McLean MP, Duan WR, Nelson SE, Albarracin CT, Khan I, Gibori G.

Endocrinology. 1992 Nov;131(5):2213-21.

PMID:
1425419

Supplemental Content

Loading ...
Support Center